Biogen Inc. reported fourth‑quarter 2025 results on February 6 2026, posting revenue of $2.28 billion—a 7.1% year‑over‑year decline from $2.455 billion in Q4 2024. Non‑GAAP earnings per share reached $1.99, beating the consensus of $1.61–$1.63 by 22.1% to 23.6% and exceeding the $1.60 estimate by $0.39. The company’s operating margin fell sharply from 18% in Q4 2024 to –2.5% in Q4 2025, reflecting a mix shift toward lower‑margin growth products and higher operating costs.
The decline in revenue was driven largely by erosion in the legacy multiple sclerosis (MS) franchise. MS revenue, excluding the newly added Vumerity, dropped to $917.2 million from $1.02 billion in the prior year, a 10.5% decline. In contrast, sales of the Alzheimer’s drug Leqembi grew to $134 million globally, up 12% from $119 million, while other growth products—Skyclarys, Zurzuvae, and Qalsody—contributed $3.3 billion to the company’s FY 2025 revenue, a 19% increase year‑over‑year. The stronger performance of these newer products offset the loss of market share in the MS portfolio, but the overall mix shift toward lower‑margin items contributed to the margin compression.
Management attributed the margin squeeze to a combination of higher operating expenses and a shift in product mix. CFO Robin Kramer noted that “total revenue is expected to decline by a mid‑single‑digit percentage for 2026 compared to 2025, driven by MS portfolio challenges and ongoing generic erosion.” CEO Chris Viehbacher emphasized that the company is “finishing the year strongly with a very good fourth quarter” and highlighted the momentum of its growth‑product portfolio, adding that Vumerity has been moved into the growth‑products category. The company’s free‑cash‑flow of $2.1 billion in FY 2025 and $4.2 billion in cash and marketable securities underscore its financial discipline amid the transition.
Biogen reiterated its 2026 guidance, projecting non‑GAAP diluted EPS between $15.25 and $16.25—well above the consensus estimate of $14.95. The company also maintained a mid‑single‑digit revenue decline outlook for 2026, reflecting continued pressure on the MS franchise. The guidance signals management’s confidence in sustaining profitability through disciplined cost management and the expanding revenue base of its growth products, even as it navigates headwinds in legacy markets.
Pre‑market trading reflected the positive reception of the results, with the stock rising 5.11% as investors weighed the earnings beat and forward guidance. Analysts cited the strong performance of Leqembi and the company’s disciplined expense management as key drivers of the market reaction, while noting that the margin compression and revenue decline in the MS segment remain a concern for the near term.
The earnings report underscores Biogen’s ongoing transition from a legacy MS franchise to a launch‑stage platform. While the company faces significant competitive pressure from generics and biosimilars in the MS market, the robust growth of its Alzheimer’s and rare‑disease products provides a tailwind that offsets the decline. The guidance and cash‑flow position suggest that Biogen is well‑positioned to invest in its pipeline, including the upcoming subcutaneous formulation of Leqembi, while maintaining profitability in a challenging market environment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.